Sangamo cuts 120 jobs, announces prioritized pipeline to extend cash runway another year
Sangamo Therapeutics is cutting 27% of its US workforce, prioritizing its pipeline and changing up its corporate structure in order to save about $31 million and stay afloat for the next 12 months.
The cell and gene therapy biotech said Wednesday it will lay off 120 people as it reduced its internal manufacturing and allogeneic research work in California. Andrew Ramelmeier, EVP of technical operations, will also be leaving the company in July.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.